相关实验视频
Updated: Sep 9, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.0K
开发一种对优糖性糖尿病酸症的管理方案
Zulma Cardona1, Jared G Friedman1, Nevin Kamal1
1Division of Endocrinology, Metabolism, and Molecular Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, 645 N Michigan Ave, Suite 530, Chicago, IL, 60611, USA.
Current diabetes reports
|September 3, 2025
概括
通常与SGLT2抑制剂有关,需要专门治疗. 使用固定的胰岛素和乳糖定位的新方案改善了eudka的管理,解决了传统dka方案的局限性.
科学领域:
- 内分泌学
- 药理学
- 内部医学
背景情况:
- 在使用-葡萄糖共传递剂2抑制剂 (SGLT2i) 时,糖尿病酸症 (euDKA) 的发生率正在上升.
- 由于葡萄糖水平正常,传统的糖尿病酸症 (DKA) 方案对eudka无效.
- 现有的指导方针并没有具体解决eudka的管理问题.
研究的目的:
- 审查有关eudka的最新数据.
- 引入一个新的euDKA管理协议.
- 解决使用SGLT2i药物治疗eudka的挑战.
主要方法:
- 关于eudka病例和结果的文献综述
- 在重症监护室开发和实施标准化的eudka治疗方案.
- 协议包括固定的胰岛素输注和含有乳糖的液体定位.
主要成果:
- 与高血糖DKA患者相比,eudka患者的住院时间更长,离子间隙的关闭速度更慢.
- 增加SGLT2i的处方与eudka的更高风险相关.
- 新协议已获得批准,目前正在使用中.
结论:
- 由于治疗的挑战,需要对eudka制定标准化方案.
- 开发的协议为euDKA管理提供了有针对性的方法.
- 需要进一步的研究来评估该方案在不同环境中的安全性和有效性.
相关概念视频
SBAR II: Application of SBAR
4.7K
SBAR is an effective communication tool used by healthcare professionals to communicate patient information accurately. SBAR stands for Situation, Background, Assessment, and Recommendation. For a better understanding, an example is given below.
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
4.7K
Hypoglycemia and Glucagon
334
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
334
Diabetes: Management and Pharmacotherapy
354
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
354
Diagnosing Acidosis and Alkalosis
512
Diagnosing acid-base imbalances involves systematically analyzing arterial blood samples, focusing on three key measurements: pH, bicarbonate (HCO3−) concentration, and carbon dioxide partial pressure (PCO2). This analysis follows a four-step process that helps identify the imbalance's underlying cause and nature.
First, the pH level is assessed to determine whether the blood pH is normal (7.35–7.45), low (acidosis), or high (alkalosis).
Next, the PCO2 and...
First, the pH level is assessed to determine whether the blood pH is normal (7.35–7.45), low (acidosis), or high (alkalosis).
Next, the PCO2 and...
512
Diabetes Mellitus: Type 2 and Gestational
2.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.9K
Insulin: Dosing Regimen and Adverse Effects
253
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
253

